US 12,233,135 B2
Therapeutic constructs for treating cancer
Christopher Ullman, Hertfordshire (GB); and Christine Anne Carrington, Cambridgeshire (GB)
Assigned to PRECISION MOLECULAR INC., Gaithersburg, MD (US)
Appl. No. 17/047,011
Filed by PRECISION MOLECULAR INC., Gaithersburg, MD (US)
PCT Filed Apr. 10, 2019, PCT No. PCT/US2019/026849
§ 371(c)(1), (2) Date Oct. 12, 2020,
PCT Pub. No. WO2019/200013, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/655,926, filed on Apr. 11, 2018.
Prior Publication US 2021/0154328 A1, May 27, 2021
Int. Cl. A61K 48/00 (2006.01); A61K 9/19 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 38/45 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/59 (2017.01); A61P 35/00 (2006.01)
CPC A61K 48/0058 (2013.01) [A61K 9/19 (2013.01); A61K 38/1774 (2013.01); A61K 38/208 (2013.01); A61K 38/45 (2013.01); A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464401 (2023.05); A61K 39/464404 (2023.05); A61K 39/464406 (2023.05); A61K 47/59 (2017.08); A61P 35/00 (2018.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/55 (2023.05)] 20 Claims
 
1. A nucleic acid construct for the treatment of cancer comprising an expression cassette, wherein the expression cassette comprises a cancer-specific promoter and nucleic acid sequences encoding one or more tumor antigens, wherein the nucleic acid sequences encoding the one or more tumor antigens are engineered to have a reduced CpG content compared to their wild-type counterparts, the nucleic acid construct comprises a CpG-free plasmid backbone, or a combination thereof.